1. Home
  2. PRPL vs SKYE Comparison

PRPL vs SKYE Comparison

Compare PRPL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

HOLD

Current Price

$5.80

Market Cap

34.1M

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.28

Market Cap

20.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
SKYE
Founded
2010
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.1M
20.0M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
PRPL
SKYE
Price
$5.80
$0.28
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$0.65
$15.00
AVG Volume (30 Days)
27.8K
531.0K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
152.75
N/A
EPS
N/A
N/A
Revenue
$468,725,000.00
N/A
Revenue This Year
$8.50
N/A
Revenue Next Year
$6.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.28
52 Week High
$10.00
$4.99

Technical Indicators

Market Signals
Indicator
PRPL
SKYE
Relative Strength Index (RSI) 45.44 17.98
Support Level $0.51 N/A
Resistance Level $10.00 $0.87
Average True Range (ATR) 0.64 0.10
MACD -0.58 -0.03
Stochastic Oscillator 0.44 2.96

Price Performance

Historical Comparison
PRPL
SKYE

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: